Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Update

Harvard Bioscience, Inc. (NASDAQ:HBIO) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 450,100 shares, an increase of 20.3% from the November 15th total of 374,100 shares. Based on an average trading volume of 144,200 shares, the days-to-cover ratio is currently 3.1 days.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its position in shares of Harvard Bioscience by 193.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock worth $649,000 after acquiring an additional 150,218 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Harvard Bioscience by 13.0% in the second quarter. Bank of New York Mellon Corp now owns 274,635 shares of the medical instruments supplier’s stock worth $783,000 after purchasing an additional 31,505 shares in the last quarter. Vanguard Group Inc. increased its holdings in Harvard Bioscience by 2.4% in the first quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock worth $9,125,000 after purchasing an additional 49,576 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Harvard Bioscience by 6.1% in the second quarter. Renaissance Technologies LLC now owns 745,278 shares of the medical instruments supplier’s stock valued at $2,124,000 after buying an additional 42,800 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Harvard Bioscience by 24.9% during the 2nd quarter. Rhumbline Advisers now owns 47,753 shares of the medical instruments supplier’s stock worth $136,000 after buying an additional 9,512 shares in the last quarter. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Trading Down 3.6 %

Shares of HBIO stock traded down $0.08 during trading hours on Friday, hitting $2.16. 212,375 shares of the company’s stock traded hands, compared to its average volume of 121,584. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. Harvard Bioscience has a 12 month low of $1.99 and a 12 month high of $5.56. The stock has a market cap of $94.22 million, a PE ratio of -6.55 and a beta of 1.27. The stock’s 50 day simple moving average is $2.33 and its 200 day simple moving average is $2.72.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.